In last trading session, Sagimet Biosciences Inc (NASDAQ:SGMT) saw 0.35 million shares changing hands with its beta currently measuring 2.13. Company’s recent per share price level of $3.22 trading at -$0.09 or -2.72% at ring of the bell on the day assigns it a market valuation of $98.77M. That closing price of SGMT’s stock is at a discount of -129.19% from its 52-week high price of $7.38 and is indicating a premium of 46.27% from its 52-week low price of $1.73. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.42 million shares which gives us an average trading volume of 524.32K if we extend that period to 3-months.
For Sagimet Biosciences Inc (SGMT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.5 in the current quarter.
Sagimet Biosciences Inc (NASDAQ:SGMT) trade information
Upright in the red during last session for losing -2.72%, in the last five days SGMT remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $3.22 price level, adding 7.47% to its value on the day. Sagimet Biosciences Inc’s shares saw a change of -28.44% in year-to-date performance and have moved -1.23% in past 5-day. Sagimet Biosciences Inc (NASDAQ:SGMT) showed a performance of 59.41% in past 30-days. Number of shares sold short was 3.89 million shares which calculate 5.36 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 46.33% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -86.34% in reaching the projected high whereas dropping to the targeted low would mean a loss of -86.34% for stock’s current value.
Sagimet Biosciences Inc (SGMT) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -16.85% during past 5 years.
Sagimet Biosciences Inc (NASDAQ:SGMT)’s Major holders
Insiders are in possession of 8.40% of company’s total shares while institution are holding 45.73 percent of that, with stock having share float percentage of 49.92%. Investors also watch the number of corporate investors in a company very closely, which is 45.73% institutions for Sagimet Biosciences Inc that are currently holding shares of the company. POINT72 ASSET MANAGEMENT, L.P. is the top institutional holder at SGMT for having 2.37 million shares of worth $8.09 million. And as of 2024-06-30, it was holding 7.414 of the company’s outstanding shares.
The second largest institutional holder is NEA MANAGEMENT COMPANY, LLC, which was holding about 2.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.2677 of outstanding shares, having a total worth of $6.84 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and BlackRock Health Sciences Term Trust are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 763.99 shares of worth $2.46 million or 2.49% of the total outstanding shares. The later fund manager was in possession of 408.12 shares on Dec 31, 2024 , making its stake of worth around $1.31 million in the company or a holder of 1.33% of company’s stock.
